FindTrial
Sign In

Administration time-dependent effects of raloxifen in postmenopausal women with osteoporosis

Administration time-dependent effects of raloxifen in postmenopausal women with osteoporosis - Chronotherapy of raloxifen

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000002322
Enrollment
64
Registered
2009-08-11
Start date
2009-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postmenopausal osteoporosis

Interventions

Morning-administration of raloxifene Evening-administration of raloxifene

Sponsors

Division of Clinical Pharmacology, Department of Pharmacology, School of Medicine, Jichi Medical University
Lead Sponsor
Hokuriku Clinical Research Supporting Center Moka Hospital Kahoku Central Hospital Nagai Internal Medicine Clinic Kanazawa Red Cross Hospital Shin-Kaminokawa Hospital
Collaborator

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Outpatients Diagnosed postmenopausal osteoporosis Need for treatment of osteoporosis Written informed consent

Exclusion criteria

Exclusion criteria: Treatment with raloxifene or bisphosphonate in the preceding 12 months Anticoagulant therapy Inpatients Current or previous venous thromboembolism Bedridden subjects Antiphospholipid antibody syndrome Possibility of pregnancy Hypersensitivity to raloxifene Severe hepatic impairment Severe renal dysfunction Other unsuitableness

Design outcomes

Primary

MeasureTime frame
Coagulation and fibrinolysis factors—

Secondary

MeasureTime frame
Bone metabolism markers Adverse reactions Bone density—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026